ProCE Banner Activity

New Therapeutic Developments for Relapsed/Refractory Multiple Myeloma

Watch this on-demand Webcast capturing a live CCO Webinar featuring expert presentations on new agents and approaches for relapsed/refractory multiple myeloma, including strategies for early relapse, BCMA-targeted treatments for late relapse, and novel targeted agents.

This educational activity is intended for clinicians practicing medicine outside of the United States.

Released: August 31, 2020

Expiration: August 30, 2021

Share

Faculty

Paula Rodriguez-Otero

Paula Rodriguez-Otero, MD, PhD

Associate Professor
Consultant in Hematology

Department of Hematology, Clínica Universidad de Navarra
University of Navarra
Pamplona, Spain

Jesus San-Miguel

Jesus San-Miguel, MD, PhD

Director of Clinical and Translational Medicine
Clinica Universidad de Navarra
Universidad de Navarra
Pamplona, Spain

Katja C. Weisel

Katja C. Weisel, MD

Professor and Leading Physician
University Medical Center Hamburg-Eppendorf
Deputy Director of II. Medical Clinic and Polyclinic, Department of Oncology, Hematology, BMT with Department of Pneumology
Co-Director of University Cancer Center Hamburg
Hamburg, Germany

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

GlaxoSmithKline

Faculty Disclosure

Primary Author

Paula Rodriguez-Otero, MD, PhD

Associate Professor
Consultant in Hematology

Department of Hematology, Clínica Universidad de Navarra
University of Navarra
Pamplona, Spain

Paula Rodriguez-Otero, MD, PhD, has disclosed that she has received consulting fees from AbbVie, Amgen, Celgene/Bristol-Myers Squibb, GlaxoSmithKline, Janssen, Kite Pharma, Oncopeptides, and Sanofi.

Jesus San-Miguel, MD, PhD

Director of Clinical and Translational Medicine
Clinica Universidad de Navarra
Universidad de Navarra
Pamplona, Spain

Jesús F. San-Miguel, MD, PhD, has disclosed that he has received consulting fees from Amgen, Bristol-Myers Squibb, Celgene, Janssen, Novartis, Sanofi, and Takeda.

Katja C. Weisel, MD

Professor and Leading Physician
University Medical Center Hamburg-Eppendorf
Deputy Director of II. Medical Clinic and Polyclinic, Department of Oncology, Hematology, BMT with Department of Pneumology
Co-Director of University Cancer Center Hamburg
Hamburg, Germany

Prof. Dr. med. Katja Weisel has disclosed that she has received funds for research support from Amgen, Celgene/Bristol-Myers Squibb, Janssen, and Sanofi and consulting fees from Adaptive Biotech, Amgen, Celgene/Bristol-Myers Squibb, GlaxoSmithKline, Janssen, Karyopharm, Sanofi, and Takeda.

Staff Disclosure

Staff

Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no relevant conflicts of interest to report.

Katie Eustace, MBA

Senior Director, Global Medical Education, Europe

Katie Eustace, MBA, has no relevant conflicts of interest to report.

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

Justine Stanley, MSc

Editorial Contributor

Justine Stanley, MSc, has no relevant conflicts of interest to report.